NEW YORK — South Korea's cosmetic surgery market continues its expansion, with niche aesthetic procedures like "elf ears" gaining traction among younger demographics. This trend highlights strong consumer appetite for elective aesthetic enhancements across the region. Industry analysts estimate the South Korean medical aesthetics market will grow nine percent annually through 2028, reaching $3.5 billion.
U.S. pharmaceutical giant AbbVie (ABBV) holds a significant position in this global market through its Allergan Aesthetics division. Allergan's portfolio includes leading neurotoxins like Botox Cosmetic and dermal fillers such as Juvederm, crucial for various facial sculpting procedures. The division reported $5.3 billion in revenue in 2024, contributing more than nine percent to AbbVie's total sales and showing consistent growth in international markets.
The sustained growth in elective aesthetic procedures, even specialized ones, provides a tailwind for the wider medical aesthetics device sector. Companies like InMode Ltd. (INMD), specializing in minimally invasive aesthetic platforms, are also positioned to benefit. InMode reported revenue of $501 million in 2024, driven by strong international sales, particularly in Asia. This demand indicates consumer willingness to invest in appearance-enhancing treatments, extending beyond traditional anti-aging.
These market dynamics serve as a catalyst for continued investment in aesthetic innovation and geographic expansion by major players. As disposable incomes rise in key Asian economies, demand for advanced cosmetic treatments is likely to increase, supporting higher procedure volumes. Analysts project the global medical aesthetics market to reach $29 billion by 2030, driven by both surgical and non-surgical segments. AbbVie's strong cash flow from its pharmaceutical segment provides capital for Allergan's expansion.
While AbbVie trades at a forward P/E of 14.5, reflecting its diversified pharmaceutical revenue, the consistent performance of its aesthetic unit often receives less attention than its immunology drugs. Investors should watch Allergan's international growth figures in future earnings calls. The segment's resilience in varied economic conditions, supported by discretionary spending, offers a stable, high-margin revenue stream.
